CClinicalTrials.gg
Active, not recruitingNCT06515496Updated Jul 23, 2024

A Clinical Trial to Examine the Efficacy of a Dietary Supplement to Improve the Health and Appearance of Hair.

An interventional study of Scale HLV Clinical Formula Hair Vitamins and Placebo in Hair Thinning and Hair Shedding, sponsored by Scale Media Inc. Active, not recruiting at 1 site in United States. Open to female participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2024-07-23.

Sponsored by Scale Media Inc · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years ago, but the record still lists the study as active, not recruiting.
  • Registered 3 months after the study started (first participant enrolled Mar 2024, registered Jul 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
35 Years and older
Sex
Female
01

Study summary

This study evaluates the efficacy of Scale Media's HLV Clinical Formula Hair Vitamins on the health and appearance of hair, focusing on growth, volume, dullness, overall health, hair shedding, fullness, and strength. It is a randomized controlled trial with 50 female-at-birth participants experiencing self-perceived hair thinning.

02

Conditions studied

  • Hair Thinning
  • Hair Shedding

Keywords

  • Hair growth
  • Female pattern hair loss
  • Hair health
03

In context

Alopecia

609 studies on the registry are indexed under Alopecia; 131 are open to participants now.

This study's planned enrollment of 100 is above the median of 45 across 513 interventional studies indexed under Alopecia.

Browse Alopecia studies →

Lead sponsor

Scale Media Inc is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Female at birth, aged 35+.
  • Self-perceived hair thinning and increased hair shedding for at least three months.
  • Consistent hair care routine for at least one month prior.
  • Willing to maintain hair care routine, diet, and refrain from new vitamins or supplements targeting hair growth during the study.
  • Generally healthy without uncontrolled chronic diseases.

Exclusion criteria

Exclusion Criteria:

  • Hair loss conditions other than female pattern baldness.
  • Pregnant, breastfeeding, or trying to conceive.
  • Currently taking iron supplements or other hair growth treatments.
  • Significant chronic conditions or planned medical procedures that interfere with protocol adherence.
  • Recent chemical hair treatments or plans for such treatments during the study.
  • Severe allergic reactions to the product's ingredients.
  • Recent surgeries, major illnesses, or undergoing chemotherapy/radiotherapy.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Intervention

    Participants in this arm will take the Scale HLV Clinical Formula Hair Vitamins.

    Dietary Supplement: Scale HLV Clinical Formula Hair Vitamins

  • Placebo comparator
    Placebo

    Participants in this arm will take a placebo product consisting of rice flour in vegetable cellulose capsules.

    Other: Placebo

Interventions

  • Dietary supplementScale HLV Clinical Formula Hair Vitamins

    For the first week, participants will take 1 capsule in the morning and 2 capsules in the evening before food. From Week 2 onwards, participants will take 3 capsules daily in the evening before food.

  • OtherPlacebo

    For the first week, participants will take 1 capsule in the morning and 2 capsules in the evening before food. From Week 2 onwards, participants will take 3 capsules daily in the evening before food.

06

What researchers measure

Primary outcomes

  1. Reduction in Hair Shedding

    Hair shedding will be measured through hair counts from the at-home comb test and hair health will be evaluated through expert dermatologist grading based on photos provided by participants.

    Time frame: Baseline, Day 90, and Day 180

Secondary outcomes

  1. Improvement in Hair Health Perception

    Participants' perceptions of the product's effect on overall hair health, including volume, dullness, fullness, and strength, will be evaluated through self-reported questionnaires.

    Time frame: Baseline, Day 30, Day 60, Day 90, Day 120, Day 150, and Day 180

07

Study locations

1 site
  • Citruslabs
    Santa Monica, California 90404, United States
08

References and documents

Individual participant data

Plan to share: Yes — The plan includes sharing individual participant data (IPD) collected during the study. The data to be shared includes de-identified individual participant data that underlie the results reported in the publication, including text, tables, figures, and appendices.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06515496
Lead sponsor
Scale Media Inc
Collaborators
Citruslabs
Responsible party
Sponsor
First posted
Jul 23, 2024
Start date
Mar 26, 2024
Primary completion
Sep 26, 2024 (estimated)
Completion
Sep 26, 2024 (estimated)
Last update
Jul 23, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion